Dr. Randy Sweis, MD

• Medical Oncology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• FGFR3Alterations in the Era of Immunotherapy for Urothelial Bladder Cancer, 2020-11-05

• Molecular Drivers of the Non-T Cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer, 2016-05-17

• Emerging role of immunotherapy in urothelial carcinoma - immunobiology/biomarkers, 2016-11-09

• 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two National Harbor, MD, USA. 9-13 November 2016, 2016-11-16

• Cost-Effectiveness of Immune Checkpoint Inhibitors in Urothelial Carcinoma-A Review, 2021-12-24

• Dynamic Contrast Enhanced-Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal Carcinoma, 2016-08-17

• Severe COVID-19 infection is associated with aberrant cytokine production by infected lung epithelial cells rather than by systemic immune dysfunction, 2021-11-24

• Low clinical adoption of tumor genomic profiling: cause for concern?, 2018-05-15

• A validated mathematical model of FGFR3-mediated tumor growth reveals pathways to harness the benefits of combination targeted therapy and immunotherapy in bladder cancer, 2021-05-19

• T cell-inflamed versus non-T cell-inflamed tumors: a conceptual framework for cancer immunotherapy drug development and combination therapy selection, 2018-09-06

• Lenvatinib in Combination With Pembrolizumab in Patients with Treatment-Naive and Treatment-Experienced Metastatic Renal Cell Carcinoma: Results From a Phase 1b/2 Study, 2021-06-15

• Complete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy, 2019-03-11

• Morphological Correlation of Urinary Bladder Cancer Molecular Subtypes in Radical Cystectomies, 2020-09-26

• Mechanistic and pharmacologic insights on immune checkpoint inhibitors, 2017-03-18

• Methods to assess anticancer immune responses in orthotopic bladder carcinomas, 2019-10-24

• Concurrent EGFR Mutation and ALK Translocation in Non-Small Cell Lung Cancer, 2016-02-26

• Characterization of oncogenic pathways linked with T cell exclusion in urothelial bladder cancer, 2015-11-04

• Tumor Endothelial Inflammation Predicts Clinical Outcome in Diverse Human Cancers, 2012-10-04

• Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder Cancer, 2019-12-01

• Wnt-ß-catenin activation epigenetically reprograms Tregcells in inflammatory bowel disease and dysplastic progression, 2021-03-04

• Germline genetic contribution to the immune landscape of cancer, 2021-02-09